BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report) fell 9% during trading on Friday. The stock traded as low as C$4.80 and last traded at C$4.88. Approximately 15,457 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 15,722 shares. The stock had previously closed at C$5.36.
BriaCell Therapeutics Stock Down 9.0%
The stock has a market cap of C$42.46 million, a price-to-earnings ratio of -5.81 and a beta of 1.88. The business’s fifty day moving average is C$5.31 and its two-hundred day moving average is C$5.15.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to developing novel immunotherapies to fight cancer and improve patients’ lives. Immunotherapies have become the forefront of the fight against cancer because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
